WallStSmart

Boston Scientific Corp (BSX)vsBrainsway Ltd (BWAY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 38338% more annual revenue ($20.07B vs $52.23M). BWAY leads profitability with a 14.6% profit margin vs 14.4%. BSX trades at a lower P/E of 35.1x. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

BWAY

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 5.5Value: 3.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
BWAYSignificantly Overvalued (-178.3%)

Margin of Safety

-178.3%

Fair Value

$8.42

Current Price

$13.50

$5.08 premium

UndervaluedFair: $8.42Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

BWAY1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
27.4%8/10

Revenue surging 27.4% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

BWAY4 concerns · Avg: 2.8/10
EPS GrowthGrowth
3.9%4/10

3.9% earnings growth

Market CapQuality
$536.38M3/10

Smaller company, higher risk/reward

P/E RatioValuation
75.9x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-2.02M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth. Revenue growth of 27.4% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : BWAY

The primary concerns for BWAY are EPS Growth, Market Cap, P/E Ratio. A P/E of 75.9x leaves little room for execution misses.

Key Dynamics to Monitor

BSX carries more volatility with a beta of 0.70 — expect wider price swings.

BWAY is growing revenue faster at 27.4% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 46/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Want to dig deeper into these stocks?